Group 1: Financial Performance - The company achieved a record high revenue in 2024, but net profit declined significantly by -83.82% [2][4] - As of April 18, 2025, the number of registered shareholders was 16,423 [3] Group 2: Strategic Initiatives - The company plans to enhance operational management through various measures, including expanding chain pharmacy construction and developing a new model for specialized pharmacies [2][4] - Establishment of a wholly-owned subsidiary, Hunan Dajia Weikang Regenerative Medicine Research Institute, aims to strengthen capabilities in medical services and research [3][4] Group 3: Market Positioning - The company is focused on integrating online and offline services, creating a comprehensive health management ecosystem [4] - Efforts are being made to improve the efficiency of the pharmaceutical supply chain and expand market share in distribution [4] Group 4: Research and Development - The company is increasing investment in R&D for traditional Chinese medicine and innovative drugs, enhancing product quality and market competitiveness [4] - Collaboration with universities and hospitals is being pursued to advance research in regenerative medicine [3][4]
达嘉维康(301126) - 湖南达嘉维康医药产业股份有限公司投资者关系活动记录表